HLB Pharmaceutical Co., Ltd.
π°π·South Korea
- Country
- π°π·South Korea
- Ownership
- Public
- Established
- 1998-04-01
- Employees
- 222
- Market Cap
- -
- Website
- http://www.hlbpharma.co.kr
Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 4:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)β’ Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 4
1 (50.0%)C-Trelin Orally Disintegrated(OD) Tablet 5mg in Ataxia Due to Spinocerebellar Degeneration
Phase 4
Completed
- Conditions
- Spinocerebellar Degeneration
- Interventions
- Drug: C-Trelin OD Tab(5mg Taltirelin Hydrate)Drug: Placebo
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- HLB Pharmaceutical Co., Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT04107740
- Locations
- π°π·
Chonnam National University Hospital, Gwangju, Korea, Republic of
π°π·Gangnam Severance Hospital, Seoul, Korea, Republic of
π°π·Korea University Anam Hospital, Seoul, Korea, Republic of
Phase 1 Single Dose Escalation Study of CTB-001
- First Posted Date
- 2012-07-24
- Last Posted Date
- 2012-07-24
- Lead Sponsor
- HLB Pharmaceutical Co., Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT01647893
- Locations
- π°π·
Asan Medical Center, Seoul,, Korea, Republic of
News
No news found